- AbbVie Features New Data Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
- ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with SOC Treatment in Patients with Indolent B-cell NHL
- Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML
- Aptose’s Tuspetinib Triple Drug Therapy demonstrated High Rate of Frontline Clinical Responses Continues Across AML Populations
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with R/R Multiple Myeloma
- AstraZeneca presents new data from its diverse pipeline and portfolio
- Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax
- Ascentage Pharma Presents Encouraging Data from Ph 1b/2 Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
- Ascentage Pharma Presents First Dataset from Ph 3 POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
- Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Ph 2 Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
- Astellas Presents New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum
- Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of MPNs
- Bristol Myers Squibb presents Data Showcasing Potential of Hematology Pipeline
- Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data
- BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve CLL
- Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia
- Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in R/R NHL
- Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049
- Dizal Showcases New Data from Golidocitinib and Birelentinib
- Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with R/R multiple myeloma
- Enterome presents strengthened interim Ph 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma
- Evaxion presents new data for EVX-04 in AML
- Faron presents updated BEXMAB data showing Deep and durable responses in HR-MDS with favorable safety profile
- Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL
- Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line DLBCL and FL
- Genmab Presents Pivotal Ph 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with R/R Follicular Lymphoma
- GSK presents new results from the DREAMM programme for belantamab mafodotin
- Halia Therapeutics Announces Positive Ph 2a Data for Ofirnoflast in Lower-Risk MDS
- HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in R/R NHL
- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML
- Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in R/R Multiple Myeloma
- K36 Therapeutics presents FIH Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement & Clinical Activity in Multiple Myeloma
- Kite Announces New Data for Pivotal iMMagine-1 Study, Highlighting Anito-cel’s Opportunity in R/R Multiple Myeloma
- Kite’s Next-Gen Bicistronic CAR T-Cell Therapies Show Encouraging Ph 1 Results in R/R B-Cell Lymphoma in New Data
- Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and R/R AML
- Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented
- Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in head-to-head Ph 3 BRUIN CLL-314 study versus Imbruvica (ibrutinib)
- Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma
- Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses
- March Biosciences Presents Positive Interim Clinical Data from Ph 2 Trial of MB-105 CD5 CAR-T Cell Therapy
- Merck Presents data Showcasing Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
- Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line R/R large B-cell lymphoma
- Molecular Partners Presents Updated Data from Ongoing Ph 1/2a Trial of MP0533 in AML
- Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Ph 1 Trial of Bexobrutideg (NX-5948) in Patients with R/R CLL
- Nurix Therapeutics Presents New Data from the Ph 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia
- OncoPrecision Announces Oral Presentation of ONC001 for Monocytic Leukemia
- Orca Bio Presents New Clinical Data on Orca-T® in Older Patients with ALL, AML & MDS Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Ph 3 Study
- Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal Ph 3 STARGLO study
- Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
- Ryvu Therapeutics Presents New Clinical Data from RIVER-81 and POTAMI-61 Studies of Romaciclib (RVU120)
- Sobi Showcases Scientific advances and Commitment to Haematology
- Secura Bio Presents Extended Follow Up Analyses from Ph 2 PRIMO Trial in Patients with R/R peripheral T-cell lymphoma
- SELLAS Life Sciences Presents Positive Ph 2 Data of SLS009 in Combination with AZA/VEN in R/R AML-MR
- Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Ph 1 Trial in R/R AML Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
- Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of CMML and AML
- Sonrotoclax Data Confirm Foundational Potential Across B-cell Malignancies
- Syndax Highlights Leadership in Menin Inhibition with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
- Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine
- Terns Highlights Additional Positive Ph 1 Data Supporting TERN-701’s Best-in-Disease Potential in R/R CML
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Ph 1 Heme Trial
- Unprecedented results from the Ph 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential SOC as early as second line for patients with R/R multiple myeloma
- Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
- Updated Results of Ph 3 ALLELE Study Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in R/R EBV+ PTLD
- Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of R/R Large B-cell Lymphoma Patients in New Analysis